Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The investigators are interested in determining if the investigators are able to detect
changes in brain chemistry using Magnetic Resonance Spectroscopy (MRS) in individuals with
Parkinson's disease (PD), those with Gaucher's disease (GD), and those without neurological
disorders (healthy controls) when they are given the antioxidant N-acetylcysteine (NAC). This
study will combine information from a medical history, a physical examination and disease
rating scales with results obtained using MRS brain scans and pharmacokinetic studies from
blood samples. This research will require 1 visit that will require about 4 to 5 hours of
time. During this study, participants will provide their medical history, be examined and
undergo a rating scale for about one hour; the brain scan and pharmacokinetic studies will
require 1.5-2 hours of time; in total the study will take about 4-5 hours.
Phase:
Phase 1
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborators:
National Center for Advancing Translational Science (NCATS) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institute of Neurological Disorders and Stroke (NINDS) Rare Diseases Clinical Research Network